Silence Therapeutics (SLN) Cash & Current Investments (2018 - 2026)

Silence Therapeutics' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $70.1 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 48.67% year-over-year to $70.1 million; the TTM figure through Mar 2026 stood at $70.1 million (down 48.67% YoY), while the FY2025 annual figure was $85.1 million, down 54.26% from the prior year.
• Cash & Current Investments came in at $70.1 million for Q1 2026 at Silence Therapeutics, down from $85.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $193.8 million in Q1 2024 to a low of $62.8 million in Q2 2023.
• A 5-year average of $108.6 million and a median of $85.1 million in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments jumped 200.46% in 2024 and plunged 54.26% in 2025, its largest moves.
• Silence Therapeutics' Cash & Current Investments stood at $68.4 million in 2022, then declined by 1.44% to $67.4 million in 2023, then surged by 176.01% to $186.1 million in 2024, then slumped by 54.26% to $85.1 million in 2025, then dropped by 17.67% to $70.1 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $70.1 million, $85.1 million, and $102.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison